Archives

by in
Entry Author Date Location
Alnylam’s Amyloidosis Drug Holds up in Second Clinical Trial 07/01/13 Boston
Constructing Innovation Supply Chains for the Pharmaceutical Industry 06/26/13 Boston
PTC Therapeutics IPO Raises $125M Despite Checkered Past 06/20/13 New York
Amicus Shelves New-Drug Filing For Fabry Disease Drug 06/17/13 New York
ASCO Wrap-Up: Cancer News from the West Coast 06/04/13 National
There’s Less Pie in the Sky as Wireless Health Gets Connected 05/30/13 San Diego
Merrimack Aims For Penny-Wise Pipeline of Cancer Drugs 05/24/13 Boston
Regeneron Eyes Potential Blockbuster With Asthma Drug 05/21/13 New York
Henri Termeer on Startups, Drug Prices, Getting Older (Part 2) 05/14/13 National
Radius Health CEO: Skin Patch Data is the Value Driver 05/13/13 Boston
Henri Termeer on Startups, Drug Prices, Getting Older (Part 1) 05/13/13 National
A Biotech Innovation Supply Chain: Reality or Fantasy? 04/22/13 National
Big Data Is BS in Healthcare. When Will It Become Real? 04/15/13 National
Fighting a Global War on Rare Diseases 03/20/13 New York
Has The Pendulum Swung Too Far in Favor of Rare Diseases? 03/14/13 Seattle
Veracyte Wins Over UnitedHealth With Thyroid Cancer Diagnostic 03/08/13 San Francisco
Kala Pharma, From MIT & Johns Hopkins, Grabs $11.5M for Eye Drugs 02/28/13 Boston
Shedding Baggage, Alnylam Turns a Corner 02/21/13 Boston
Poll: Which of These 10 New Drugs Is Priced Too High? 02/11/13 National
Alnylam Gets $25M From Medicines Co. for Cholesterol Drug 02/04/13 Boston
East Coast Life Sciences Roundup: Sarepta, Vertex, Celsion, More 02/01/13 Boston
FDA OKs First-in-Class Drug From Isis for Rare Cholesterol Disorder 01/29/13 San Diego
Keryx Finally Succeeds With a Clinical Trial, for Kidney Disease Drug 01/28/13 New York
Biogen ALS Failure Highlights Clinical Trial Frustrations 01/10/13 Boston
Biogen Idec’s ALS Drug Fails Phase III Trial 01/03/13 Boston
Xconomy Boston’s Top 20 Stories of the Year: Editor’s Picks 12/26/12 Boston
Xconomist of the Week: Alexis Borisy Still Likes Early Stage Biotechs 12/20/12 Boston
Ultragenyx Pharmaceutical Obtains $75,000,000 Series B Round 12/20/12 San Francisco
East Coast Life Sciences Roundup: Selecta, Rib-X, Cambridge, & More 11/30/12 Boston
Rib-X Closes First Tranche of $67.5 Million Preferred Stock Financing 11/29/12 Boston
Page 3 of 5 « previous page · next page »